Perioperative #nivolumab did not improve relapse free survival (RFS) in early stage #RCC. This was illustrated in phase III PROSPER trial that randomized 819 RCC patients at high risk for recurrence to either perioperative nivolumab or surgery alone. RFS was similar between the arms (HR: 0.97; P = 0.43). OS was not mature at the time of analysis but was not different between study arms (HR: 1.48; P = 0.93).
Perioperative #nivolumab did not improve relapse free survival (RFS) in early stage #RCC. This was illustrated in phase III PROSPER trial that randomized 819 RCC patients at high risk for recurrence to either perioperative nivolumab or surgery alone. RFS was similar between the arms (HR: 0.97; P = 0.43). OS was not mature at the time of analysis but was not different between study arms (HR: 1.48; P = 0.93).
.png)